We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Personal Continuous Glucose Monitoring Device Validated

By HospiMedica International staff writers
Posted on 17 Sep 2008
A personal continuous glucose-monitoring (CGM) device significantly reduced the average blood glucose levels (A1c) of adult patients with type 1 diabetes. More...
This further validated the ability of the device to substantially improve diabetes management and glucose control. Reducing A1c can result in reduced risk of long-term side effects associated with diabetes, including blindness and kidney disease.

A multicenter, 322-patient trial, funded by the Juvenile Diabetes Research Foundation (JDRF; New York, NY, USA), found that after six months adults using the personal CGM realized a statistically significant 0.53% absolute reduction in A1c as compared to the control group. All patients in the study experienced statistically significant absolute reductions in A1c levels ranging from 0.5-0.7% when the personal CGM was used at least six days a week. Moreover, improvements in A1c occurred without an increase in severe hypoglycemia (low blood sugar).

Medtronic (Northridge, CA, USA) currently markets the integrated diabetes management system that combines the personal CGM with insulin pump therapy. It is called the MiniMed Paradigm Real-Time system. Medtronic also offers a stand-alone personal CGM device--the Guardian Real-Time system.

Medtronic is a world leader in advanced diabetes management solutions. Their products include integrated diabetes management systems, insulin pump therapy, continuous glucose monitoring systems, and therapy management software.

"We are confident that the JDRF study results will aid physicians' efforts to bring personal CGM to more patients,” said Chris O'Connell, president of the diabetes business at Medtronic. "In fact, healthcare insurers are already seeing value in this technology. Many have policies for personal CGM devices, and new coverage decisions are being made regularly.”

Results from the multicenter study were presented on September 8, 2008, during the European Association for the Study of Diabetes annual meeting in Rome, Italy, and portions of the data will be published in the October 2, 2008, issue of the New England Journal of Medicine, which is also available online.

Related Links:
Juvenile Diabetes Research Foundation
Medtronics


Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Digital Color Doppler Ultrasound System
MS22Plus
MRI System
nanoScan MRI 3T/7T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.